article thumbnail

STAT+: Generic GLP-1 drugs could help Medicare drive a harder bargain for Ozempic and Wegovy

STAT

The advent of the first generic GLP-1 drugs could help Medicare negotiate a lower price for the highly sought after diabetes and obesity medication semaglutide , according to experts familiar with the price-negotiation program and STAT’s review of documents from the first round of negotiations.

article thumbnail

STAT+: Novo asks FDA to bar compounders from making Ozempic copies

STAT

But Novo argued that semaglutide, marketed as Ozempic for diabetes and Wegovy for obesity, should be on the FDA’s “Demonstrable Difficulties for Compounding Lists,” which are lists of complex medications that compounders are not allowed to make regardless of shortages, according to documents the agency posted this week.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

STAT+: Pharmalittle: We’re reading about a Zepbound-Wegovy faceoff, compounders slamming Novo, and more

STAT

It mirrors results seen in the companies’ diabetes drugs, which use the same active ingredients. Food and Drug Administration that semaglutide — the key ingredient in its diabetes and obesity drugs — should be added to a list of medicines that are too difficult to compound.

article thumbnail

STAT+: Pharmalittle: Chinese drugmakers develop copycat weight loss drugs; SEC eyes supplier of research monkeys

STAT

The Chinese companies hope to compete with the Danish pharma group Novo Nordisk’s pioneering drugs in China, which has the world’s largest overweight and diabetic population. If successful, they could also potentially offer a cheaper alternative in the West. And the SEC wants to know whether Inotiv complied with the U.S.

article thumbnail

STAT+: Pharmalittle: We’re reading about an Amgen obesity drug, a Senate bill on shortages, and more

STAT

Back in 2004, Gilead explained its decision by maintaining the medicines were not sufficiently different, but internal documents produced in court suggested the company made this move in order to maximize profits. Topline data are expected late this year. Continue to STAT+ to read the full story…

article thumbnail

STAT+: Pharmalittle: We’re reading about Novo targeting compounded obesity drugs, an Amgen ‘at risk’ launch, and more

STAT

The FDA still has to make a decision on whether to officially place semaglutide on the lists.

article thumbnail

California’s low-cost insulin plans receive $100m manufacturing boost

Pharmaceutical Technology

The documents state that a partnership with a CMO would be cheaper than the state directly manufacturing insulin. The bill still must pass the Senate, and moreover, how uninsured people with diabetes will deal with steep prices still remains a question. In-house manufacturing the norm. Industry split over the pricing issues.